Intra-antral application of an anti-fungal agent for recurrent maxillary fungal rhinosinusitis: a case report by Adekunle D Dunmade et al.
JOURNAL OF MEDICAL
CASE REPORTS
Dunmade et al. Journal of Medical Case Reports 2012, 6:245
http://www.jmedicalcasereports.com/content/6/1/245CASE REPORT Open AccessIntra-antral application of an anti-fungal agent for
recurrent maxillary fungal rhinosinusitis: a case
report
Adekunle D Dunmade, Olushola A Afolabi*, Biodun S Alabi, Segun Segun-Busari and Olubisi A KoledoyeAbstract
Introduction: Fungal infection of the paranasal sinuses is an increasingly recognized entity both in
immunocompetent and immunocompromised individuals. Treatment has been via use of either surgical or medical
modalities, or a combination of the two. Here, we present a case of utilization of intra-antral application of an anti-
fungal agent in the management of recurrent fungal sinusitis in an indigent Nigerian patient.
Case presentation: We present the case of a 30-year-old West African Yoruba man, an indigent Nigerian
clergyman, who presented to our facility with a history of recurrent nasal discharge (about one year), recurrent
nasal blockage (about five months), and right facial swelling (about one week). After intra-nasal antrostomy for
debulking with a systemic anti-fungal agent, our patient had a recurrence after four months. Our patient
subsequently had an intra-antral application of flumetasone and clioquinol (LocacortenW-VioformW) weekly for six
weeks with improvement of symptoms and no recurrence after six months of follow-up.
Conclusions: We conclude that topical intra-antral application of anti-fungal agents is effective in patients with
recurrent fungal maxillary sinusitis after surgical debulking.
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Fungal rhinosinusitis is a form of chronic rhinosinusitis
(CRS), which is an inflammatory disorder of the nose
and paranasal sinuses. It is clinically defined as persist-
ence of symptoms of nasal blockage or discharge for at
least 12 weeks combined with endoscopic abnormalities
(polyps, mucopurulent discharge, mucosal swelling) or
an abnormal sinus on computed tomography (CT) scan
findings; it may be primary or secondary fungal infec-
tion. Other symptoms may include facial pain or a
reduced sense of smell [1]. While allergy and bacterial
infection play a role in the etiology of this clinical condi-
tion, it is best considered as a multi-factorial chronic in-
flammatory disorder. It is distinguished from allergic
rhinitis by the involvement of both the nose and the
paranasal sinuses.* Correspondence: droaafolabi@yahoo.com
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reproduction in any medium, provided the orFungal infection of the paranasal sinuses is an increas-
ingly recognized entity both in immunocompetent and
immunocompromised individuals. It is not an uncommon
condition. In patients who are immunosuppressed, the
fungus is typically invasive and can manifest in an acute
invasive or a more chronic invasive form [2]. The treat-
ment for this is well documented in the literature and
consists of a combination of surgical and medical therapy,
including systemic anti-fungal therapy. Invasive fungal
disease is a unique entity and represents angio-invasive
fungal propagation in the immunocompromised host set-
ting. This is not the common mode of presentation of
chronic rhinosinusitis of bacterial origin in the vast ma-
jority of patients with chronic sinus issues. In patients
who are immunocompetent, fungus may be involved in
several forms. Fungal ball development is well documen-
ted and was previously termed mycetoma. It is a slow-
growing fungal collection in an abnormal sinus. Surgical
evacuation is a definitive treatment for this condition.
Anti-fungal agents can be used as systemic medica-
tions or as topical preparations delivered directly to theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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venously. Topical treatments can be given using different
delivery systems. Topical therapy may be administered
by douching, nebulization, atomization, inhalations, irri-
gation, spray, drops or powder insufflations. There is a
significant difference in the distribution of medication to
the paranasal sinuses before and after sinus surgery [3].
Early diagnosis is vital to reduce morbidity and avoid
vascular invasion and its associated complications. We
evaluated the utilization of intra-antral topical anti-
fungal agent application in the management of recurrent
inflammatory fungal maxillary sinusitis in an indigent
Nigerian patient.
Case presentation
We present the case of a 30-year-old West African Yoruba
man, an indigent Nigerian clergyman, who presented
to our facility with recurrent nasal discharge of a his-
tory of about one year, recurrent nasal blockage of a history
of about five months, and right facial swelling of a history
of about one week. The nasal discharge was bilateral,
mucopurulent, brownish, foul smelling, associated with ex-
cessive sneezing accompanied with intermittent bilateral
nasal obstruction five months prior to presentation. TheErosionof the anteriorandmedial
wall of the left antrum
Figure 1 Computed tomography scan (axial) of our patient, showing
erosion of the anterior and medial walls..obstruction started from the right nasal cavity and subse-
quently involved the left side to become bilateral with an
associated inability to perceive smell and no history of epi-
staxis. The right cheek swelling was noticed a week prior
to presentation, progressive and associated with facial pain.
A nasal examination revealed a pale polypoidal mass in
both nasal cavities, characteristic of nasal polyps that do
not bleed on touch, with associated mucopurulent sinona-
sal discharge. No other mass was seen.
A CT scan of the paranasal sinuses showed an iso-
dense lesion in both nasal cavities, maxillary antral and
ethmoid, with erosion of the medial and anterior walls
of the right maxillary antrum (Figure 1).
Our patient had a bilateral nasal polypectomy and
intra-nasal inferior meatal antrostomy performed and
blackish debris was seen in both the nasal and antral
cavities. The antrostomy was widened with a Watson-
Williams rasp. The operative findings were a pale glis-
tening mass and black-greyish materials in both nasal
and antral cavities, and mucopurulent aspirate from the
right antrum.
The surgical specimens were sent for fungal studies
and histopathology. Fungal studies yielded trichophyton
mentagrophytes and the histopathology result showedthe isodense lesion within the right maxillary antrum and slight
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nafine 250mg daily for two weeks, within which time the
symptoms subsided. Our patient failed to turn up for
follow-up. Our patient presented again four months after
surgery with a recurrent right cheek swelling; an X-ray
of the paranasal sinuses showed opacification of both
maxillary sinuses with erosion of the anterior and medial
walls as earlier noted.
Our patient had a bilateral antral washout with warm
saline under local anesthesia using the previously made
antrostomy. Our patient was then given a trial of flume-
tasone and clioquinol (LocacortenW-VioformW; double
dilution) intra-antral application after informed consent
was obtained. A nasal spray with 4% plain xylocaine was
applied to the nasal cavity; flumetasone and clioquinol
solution was then applied with our patient in a sitting
position and neck slightly extended. An antral cannula
was introduced into the maxillary antrum through an
old inferior meatal antrostomy (surgically created fis-
tula). Aspiration of the antral content was performed
with subsequent introduction of the agent (flumetasone
and clioquinol) with a volume of about 5mL into the
cavity. An initial pre-application photograph was also
obtained from our patient after informed consent was
granted. This was repeated serially weekly for six weeks
and close follow-up and monitoring of our patient were
performed. After the first dose, there was remission of
the right cheek swelling, but persistent nasal discharge.
After the second dose the nasal discharge stopped with
continuous regression of the mass.
A third dose was administered, and our patient suc-
cessfully presented for the fourth, fifth and sixth dose.
An antral aspirate yielded 3.6mL of straw-colored fluid
that was sent for cytology and fungal studies. The results
of these studies were negative for fungal and bacterial
growth. There was improvement in our patient’s symp-
toms such as nasal clearance and facial pain, which
reduced significantly. Our patient has been symptom
free for the past four months after administration of the
medication intra-antrally.
Discussion
CRS has a significant impact on the quality of life and
health burden in the adult population [4]. The impact of
the disease on quality of life, as measured by Short-Form
36 (SF-36) questionnaire scores, is comparable to or
worse than that of other chronic conditions such as
chronic obstructive pulmonary disease, congestive heart
failure and back pain [5]. Systemic anti-fungals have sig-
nificant side effects, particularly with regard to hepatic
and renal toxicity; topical fluconazole is a member of the
new class of triazole anti-fungal agents and is a potent
and specific inhibitor of fungal sterol synthesis. Its activ-
ity has been demonstrated against opportunistic mycosissuch as infection with Candida spp. including intra-
cranial infections with Microsporium spp., and with
Trichophyton spp. It can also be used for systemic infec-
tions including systemic candidiasis, coccidioidomycosis
and cryptococcosis. It is highly specific for fungal cyto-
chrome p-450 dependent enzyme. Its major route of ex-
cretion is renal, with about 80% appearing in urine
unchanged. To the best of our knowledge, its use in para-
nasal sinus fungal infection has not been previously estab-
lished in the literature. Previously, other researchers have
documented the use of amphotericin B. Topical ampho-
tericin is expensive and also associated with potential ad-
verse events [6]. With the potential for fungus to be a
common mediator of CRS, and a patient population of over
60 million in the United States of America and European
Union, it is essential that the adverse effects of anti-fungals
for CRS are well documented prior to the widespread intro-
duction of this form of therapy [7].
Previously, other authors proposed an argument
against the use of topical anti-fungals based on the fact
that fungi are ubiquitous in the sinonasal cavities, in-
cluding in normal subjects. However, it has been argued
that there may be a specific immune response driven by
fungal antigens in patients with CRS [7]. In light of these
conflicting results, it is difficult to draw any definitive
conclusions for the use of topical anti-fungals at present.
Previous studies have tried once-weekly treatment with
fluconazole in onychomycosis [8] and tinea capitis [9].
Disease severity was measured with four widely
accepted score systems. First, a modified CT score devel-
oped by Lund and Mackay [10]; the computed tomog-
raphy that our patient had prior to the surgery was in
support of the clinical diagnosis. Second, a modified rhi-
nosinusitis symptom score by Lund and Kennedy [11]
using the symptoms score that our patient had before
and after treatments has shown a significant improve-
ment after the start of treatment with the topical anti-
fungal agent, such as reduction in facial pain and nasal
blockage. Third, a rhinosinusitis quality of life score
modified after Juniper et al. [12], and finally, an endos-
copy score for nasal polyps developed by Malm [13],
which has also significantly improved ethical problems
as well as the financial problems that arose with the con-
trol CT at the end of the treatment (our patient could
not afford the cost of the scan). The pre-operative CT
scan requested took more than a month before our pa-
tient could do the scan.
Fungal infection of the paranasal sinuses is an increas-
ingly recognized entity both in normal and immuno-
compromised individuals; the retroviral screening in our
patient’s case was negative and our patient was not
known to have diabetes mellitus. Paranasal sinus mycosis
from previous studies appears to manifest as two distinct
entities, a benign or non-invasive infection and the more
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promised individuals; the latter is characterized by its
rapid onset, ability to invade tissue and destruction of
tissue (in the CT findings from our patient there was
also invasion of the anterior wall of the right maxillary
sinus [10]).
With the use of systemic anti-fungal (terbinafine
250mg daily for two weeks) drugs, there was recurrence
of the right facial swelling after four months as against
application of flumetasone and clioquinol (double dilution)
weekly for six weeks. There was no recurrent facial swelling
after six months of follow-up.
Conclusions
In summary, use of topical anti-fungal agents for fungal
sinusitis is better for patients who have had clearance or
debulking of fungal debris in the sinuses, and will help
minimize the toxicity associated with systemic anti-
fungal agents.
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